This article is
- freely available
Applications of Cell-Penetrating Peptides for Tumor Targeting and Future Cancer Therapies
Department of Neurochemistry, The Arrhenius Laboratories for Natural Sciences, Stockholm University, Svante Arrhenius väg 21A, SE-106 91 Stockholm, Sweden
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Mahidol University, 447 Sri-Ayudhya Rd. Bangkok 10400, Thailand
* Author to whom correspondence should be addressed.
Received: 21 August 2012; in revised form: 30 August 2012 / Accepted: 6 September 2012 / Published: 12 September 2012
Abstract: Cell-penetrating peptides provide a highly promising strategy for intracellular drug delivery. One relevant clinical application of cell-penetrating peptides is cancer therapeutics. Peptide based delivery could increase the uptake of drugs in tumor cells and thereby increase the efficacy of the treatment, either of conventional small molecular drugs or oligonucleotide based therapeutics. This review is focused on the cancer applications of cell penetrating peptides as delivery systems; different aspects of drug loading, cargoes and delivery are discussed together with methods for targeted delivery, activatable cell-penetrating peptides and transducible agents coupled to cell-penetrating peptides.
Keywords: cell penetrating peptides; cancer; drug delivery; oligonucleotides; siRNA therapeutics; cell targeting peptides
Article StatisticsClick here to load and display the download statistics.
Notes: Multiple requests from the same IP address are counted as one view.
Cite This Article
MDPI and ACS Style
Regberg, J.; Srimanee, A.; Langel, Ü. Applications of Cell-Penetrating Peptides for Tumor Targeting and Future Cancer Therapies. Pharmaceuticals 2012, 5, 991-1007.
Regberg J, Srimanee A, Langel Ü. Applications of Cell-Penetrating Peptides for Tumor Targeting and Future Cancer Therapies. Pharmaceuticals. 2012; 5(9):991-1007.
Regberg, Jakob; Srimanee, Artita; Langel, Ülo. 2012. "Applications of Cell-Penetrating Peptides for Tumor Targeting and Future Cancer Therapies." Pharmaceuticals 5, no. 9: 991-1007.